drugset / Trial / NCT01274403

A Randomized Study With Oral Melphalan + Prednisone (MP) Versus Melphalan, + Prednisone + Thalidomide (MPT) for Newly Diagnosesd Elderly Patients With Multiple Myeloma

NCT01274403 ↗

Phase 2 Completed 130 enrolled Gruppo Italiano Studio Linfomi
RandomizedOpen-label

Summary

The aim of the study is to compare efficacy and toxicity of melphalan and prednisone versus meplhalan, prednisone and Thalidomide in elderly patients with multiple myeloma or patients with multiple myeloma but not eligible for high dose treatment with stem cells support.

Timeline

Start
—
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Thalidomide Other / unclassified — —
Background Melphalan Small molecule — —
Background Prednisone Other / unclassified — —

Indications